$BRVE

Stifel maintained a Buy rating and $45 target on Braveheart Bio (BRVE) after the company presented at its Virtual Cardiometabolic Forum. BRVE's stock is down 13.6% over the past week, trading near its 52-week low. Management expressed confidence in BHB-1893, their drug candidate for hypertrophic cardiomyopathy. Upcoming catalysts include phase 2 and phase 3 trial data. Multiple analysts have recently rated BRVE positively, with targets ranging from $40 to $48.

Braveheart Bio Inc. shares rose 5.50% to $29.24 after initiating a Phase 3 trial for its heart drug BHB-1893. The company reported Q2 2026 financials, with R&D expenses at $11.1M and a net loss of $18.6M. Analysts have a Strong Buy consensus with an average price target of $45.25.

Goldman Sachs reiterated a buy rating on Braveheart Bio (BRVE) with a $48 price target, suggesting 80% upside from its current price. The biotech firm has a Strong Buy consensus among analysts, with targets ranging from $40 to $48. Recent analyst reports highlight progress in key trials and promising data for BHB-1893, a cardiac myosin inhibitor.

Goldman Sachs recommends two under-the-radar IPO stocks: Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE). LTGO, which develops non-opioid pain relief drugs, raised $345.6M in its IPO and has a market cap of $1.5B. Goldman's analyst sets a $73 price target, implying a 217% gain. BRVE focuses on hypertrophic cardiomyopathy treatments and plans Phase 3 trials next year. Both stocks have unanimous 'Buy' ratings from analysts.

Braveheart Bio Inc (BRVE) filed its Q2 2026 10-Q, showing a GF Score of 8/100, reflecting financial challenges but potential growth. The company's flagship product, BHB-1893, targets hypertrophic cardiomyopathy (HCM). BRVE raised $439.9M in its IPO and faces risks from financial instability and reliance on a single product.

Braveheart Bio (Nasdaq: BRVE) completed its IPO, raising $122.8 million. The proceeds will fund its lead drug candidate, BHB-1893, for hypertrophic cardiomyopathy. The company reported Q2 2026 R&D expenses of $11.1 million and a net loss of $18.6 million. Cash reserves increased to $122.8 million as of June 30, 2026.

Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After G

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E

Analysts made several calls on Monday. Morgan Stanley initiated Attovia Therapeutics with an overweight rating and $39 target. UBS upgraded Kaiser Aluminum to buy with an $184 target. Baird upgraded Deere to outperform. Jefferies reiterated Apple as underperform, citing potential downside risks. Bernstein reiterated SpaceX as outperform but noted uncertainty in its direct-to-device mobile business. Melius reiterated Nvidia as buy, suggesting potential upside. Goldman Sachs initiated Braveheart B

Analysts initiated coverage on five companies: Evercore ISI rated Lumentum (LITE) Outperform with $1,100 target; BTIG rated Smith & Nephew (SNN) Neutral; Morgan Stanley rated Attovia (ATTO) Overweight with $39 target; Roth Capital rated Ticketplus (TP) Buy with $14 target; Stifel rated Braveheart Bio (BRVE) Buy with $45 target.